Articles

In the first trial with this treatment regimen, quadruplet induction with Isa-KRd in patients with high-risk MM demonstrated promising activity and a tolerable safety profile. Read More ›

Implementation of a pharmacist on the healthcare team can have significant clinical and economic benefits. Read More ›

Updated results from a phase 1 trial of subcutaneous isatuximab via OBDS continue to demonstrate an excellent local tolerability with comparable efficacy. Read More ›

Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy. Read More ›

Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients. Read More ›

A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma. Read More ›

A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, was more effective at preventing disease progression and is better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that is the current standard of care for this population of patients. Read More ›

The use of low-molecular-weight heparin (LMWH) did not improve the rate of live births among pregnant women with inherited thrombophilia and recurrent miscarriage, according to results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition. Read More ›

Using circulating tumor cell (CTC) count to guide the choice of first-line treatment—chemotherapy or endocrine therapy—improved overall survival (OS) compared with investigator’s choice of treatment for patients with metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to results from the STIC CTC trial, which were discussed at the 2022 San Antonio Breast Cancer Symposium (SABCS) by François-Clément Bidard, MD, PhD, Co-Coordinator, Breast Cancer Research, Institut Curie, Paris, France, and Professor, Medicine, Department of Medical Oncology, Institut Curie and Université de Versailles Saint-Quentin-en-Yvelines, France. Read More ›

In patients with hormone receptor (HR)-positive, HER2-low or -negative, locally advanced or metastatic breast cancer resistant to aromatase inhibitors, the addition of the investigational first-in-class AKT inhibitor capivasertib (AZD5363) to fulvestrant (Faslodex) led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with placebo plus fulvestrant. The PFS benefit observed with capivasertib was even greater in a subset of patients with an AKT pathway alteration. Read More ›